Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms
Taymeyah Al‐Toubah, Þorvarður R. Hálfdánarson, Jennifer Gile, et al.
ESMO Open (2021) Vol. 7, Iss. 1, pp. 100364-100364
Open Access | Times Cited: 34

Showing 1-25 of 34 citing articles:

European Neuroendocrine Tumor Society (ENETS) 2023 guidance paper for digestive neuroendocrine carcinoma
Halfdan Sørbye, Enrique Grande, Marianne Pavel, et al.
Journal of Neuroendocrinology (2023) Vol. 35, Iss. 3
Open Access | Times Cited: 92
Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms
Jennifer R. Eads, Þorvarður R. Hálfdánarson, Tim Asmis, et al.
Endocrine Related Cancer (2023) Vol. 30, Iss. 8
Open Access | Times Cited: 19
Comprehensive genomic and transcriptomic characterization of high-grade gastro-entero-pancreatic neoplasms
Valentina Angerilli, Giovanna Sabella, Michele Simbolo, et al.
British Journal of Cancer (2024) Vol. 131, Iss. 1, pp. 159-170
Open Access | Times Cited: 6
Competing risk nomogram and risk classification system for evaluating overall and cancer-specific survival in neuroendocrine carcinoma of the cervix: a population-based retrospective study
Jianjun Liu, Yong Lyu, Yao He, et al.
Journal of Endocrinological Investigation (2024) Vol. 47, Iss. 6, pp. 1545-1557
Open Access | Times Cited: 5
Clinicopathological characteristics of gastric neuroendocrine neoplasms: A comprehensive analysis
Mengli Zi, Yubo Ma, Jinxia Chen, et al.
Cancer Medicine (2024) Vol. 13, Iss. 4
Open Access | Times Cited: 4
PRRT in high‐grade digestive neuroendocrine neoplasms (NET G3 and NEC)
Halfdan Sørbye, Grace Kong, Simona Grozinsky‐Glasberg, et al.
Journal of Neuroendocrinology (2024)
Open Access | Times Cited: 4
Liver Transplantation for Non-Hepatocellular Carcinoma: Role of Immune Checkpoint Inhibitors
Pegah Bahrami, Mohammad Al Zein, Ali H. Eid, et al.
Journal of Clinical and Experimental Hepatology (2025), pp. 102558-102558
Closed Access
Immuntherapie bei neuroendokrinen Neoplasien des Gastrointestinaltrakts
Sebastian Krug, Leonidas Apostolidis
Deleted Journal (2025)
Closed Access
Metastatic small cell neuroendocrine carcinoma of the ileo-caecal junction presenting with tumour perforation - case report of a rare tumour at an unusual site with an uncommon presentation, and literature review
Venkatesh Arumuga Nainar, Navin Sundar Arunachalam Jeykumar, Balamourougan Krishnaraj, et al.
Gastrointestinal Tumors (2025) Vol. 12, Iss. 1
Open Access
Therapy Resistant Gastroenteropancreatic Neuroendocrine Tumors
Kristen McClellan, Emerson Y. Chen, Adel Kardosh, et al.
Cancers (2022) Vol. 14, Iss. 19, pp. 4769-4769
Open Access | Times Cited: 12
Immune checkpoint blockade for locally advanced or recurrent/metastatic cervical cancer: An update on clinical data
Zhuo Song, Kun Zou, Lijuan Zou
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 11
Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas
Nitya Raj, Jennifer A. Chan, Stephanie J. Wang, et al.
British Journal of Cancer (2023) Vol. 129, Iss. 2, pp. 291-300
Closed Access | Times Cited: 6
Tyrosine Kinase Inhibitors and Immunotherapy Updates in Neuroendocrine Neoplasms
Osama Mosalem, Mohamad Bassam Sonbol, Þorvarður R. Hálfdánarson, et al.
Best Practice & Research Clinical Endocrinology & Metabolism (2023) Vol. 37, Iss. 5, pp. 101796-101796
Closed Access | Times Cited: 5
Progress in immunotherapy for neuroendocrine neoplasm of the digestive system
Wei-Xuan Pan, Xin-Mu Zhang, Shaolong Hao, et al.
World Journal of Gastroenterology (2023) Vol. 29, Iss. 26, pp. 4174-4185
Open Access | Times Cited: 5
Ipilimumab and nivolumab for recurrent neuroendocrine cervical carcinoma
Mary Towner, Karen F. Novak, Young Kwang Chae, et al.
Gynecologic Oncology Reports (2022) Vol. 42, pp. 101039-101039
Open Access | Times Cited: 9
Evaluation of PD-L1 expression in a large set of gastroenteropancreatic neuroendocrine tumours and correlation with clinicopathological data
Erik Rösner, Daniel Kaemmerer, Jörg Sänger, et al.
Translational Oncology (2022) Vol. 25, pp. 101526-101526
Open Access | Times Cited: 8
Treatment modalities favoring outcome in well-differentiated neuroendocrine tumors G3
Martina Hinterleitner, Ruben Pfeiffer, Nils F. Trautwein, et al.
Frontiers in Endocrinology (2024) Vol. 14
Open Access | Times Cited: 1
Enhancing treatment strategies for small bowel cancer: a clinical review of targeted therapy and immunotherapy approaches
Mehrshad Ebrahimpour, Hamidreza Hosseinzadeh, Farshad Abedi, et al.
Naunyn-Schmiedeberg s Archives of Pharmacology (2024) Vol. 397, Iss. 7, pp. 4601-4614
Closed Access | Times Cited: 1
Prolonged Response to Dabrafenib/Trametinib in Grade 3 Metastatic Pancreatic Neuroendocrine Tumor (NET G3) with BRAF V600E Mutation
Benjamin E. Ueberroth, Christopher H. Lieu, Robert W. Lentz
Journal of Gastrointestinal Cancer (2024) Vol. 55, Iss. 3, pp. 1448-1452
Open Access | Times Cited: 1
Exploring Real World Outcomes with Nivolumab Plus Ipilimumab in Patients with Metastatic Extra-Pulmonary Neuroendocrine Carcinoma (EP-NEC)
Amr Mohamed, Namrata Vijayvergia, Matthew Kurian, et al.
Cancers (2022) Vol. 14, Iss. 11, pp. 2695-2695
Open Access | Times Cited: 6
Artificial Intelligence-Powered Whole-Slide Image Analyzer Reveals a Distinctive Distribution of Tumor-Infiltrating Lymphocytes in Neuroendocrine Neoplasms
Hyung-Gyo Cho, Soo Ick Cho, Sangjoon Choi, et al.
Diagnostics (2022) Vol. 12, Iss. 10, pp. 2340-2340
Open Access | Times Cited: 6
Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review
Bryan Khuong Le, Patrick W. McGarrah, Alan Paciorek, et al.
Clinical Genitourinary Cancer (2023) Vol. 21, Iss. 3, pp. 403-414.e5
Open Access | Times Cited: 3
Targeted radionuclide therapy in endocrine-related cancers: advances in the last decade
Taymeyah Al‐Toubah, Jonathan Strosberg, Julie Hallanger‐Johnson, et al.
Frontiers in Endocrinology (2023) Vol. 14
Open Access | Times Cited: 3
Primary neuroendocrine tumors and primary neuroendocrine carcinomas of the liver: a proposal for a multidiscipline definition
Michael Torbenson, Sudhakar K. Venkatesh, Þorvarður R. Hálfdánarson, et al.
Human Pathology (2022) Vol. 132, pp. 77-88
Open Access | Times Cited: 5
The Landscape and Clinical Application of the Tumor Microenvironment in Gastroenteropancreatic Neuroendocrine Neoplasms
Shuaishuai Xu, Chanqi Ye, Ruyin Chen, et al.
Cancers (2022) Vol. 14, Iss. 12, pp. 2911-2911
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top